<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071837</url>
  </required_header>
  <id_info>
    <org_study_id>APG101_CD_002</org_study_id>
    <nct_id>NCT01071837</nct_id>
  </id_info>
  <brief_title>APG101 in Glioblastoma</brief_title>
  <official_title>A Phase II, Randomized, Open-label, Multi-centre Study of Weekly APG101 + Reirradiation Versus Reirradiation in the Treatment of Patients With First or Second Progression of Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apogenix GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apogenix AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study of APG101 + reirradiation (RT) versus reirradiation. Patients&#xD;
      suffering from a malignant brain tumor called glioblastoma having a first or second&#xD;
      progression can be included. They will be randomized to RT or RT + APG101.&#xD;
&#xD;
      APG101 is a fusion protein (similar to an antibody) and will be administered as a weekly&#xD;
      infusion. Patients can stay in this study as long as they benefit from the participation (no&#xD;
      fixed end).&#xD;
&#xD;
      In this trial, 30-35 sites in Germany, Austria and Russia take part.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase II trial, patients with a recurrence / progression of glioblastoma (first or&#xD;
      second progression) either not being eligible for tumour resection or having macroscopic&#xD;
      residual tumour after resection of the recurrence can be included (tumor size must 1-4 cm in&#xD;
      T1-weighted MRI). They must be candidates for a re-irradiation and will then be randomized in&#xD;
      a 1:2 ratio to re-irradiation alone or re-irradiation + 400mg APG101 as a weekly intravenous&#xD;
      infusion.&#xD;
&#xD;
      Radiotherapy (RT) is considered standard of care and not a study procedure. As prior&#xD;
      therapies, a first radiotherapy (maximal dose of 60 Gy; at least 8 months since the end of&#xD;
      preirradiation), a prior surgery (at least for histology) and at least one&#xD;
      Temozolomide-containing chemotherapy are mandatory; patients with prior treatment with&#xD;
      bevacizumab, iodine seeds and/or brachytherapy are not eligible. The patients' steroid dose&#xD;
      must be stable or decreasing upon inclusion.&#xD;
&#xD;
      The number of patients to be included in this study is up to 83 (depending on the statistical&#xD;
      2-step SIMON design).&#xD;
&#xD;
      Primary objective: 6 months rate of progression free survival (PFS6). Subjects can&#xD;
      participate in this study as long as a clinical benefit is considered by the treating&#xD;
      physician.&#xD;
&#xD;
      MRI tumour imaging will be carried out every 6 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 months rate of progression free survival (PFS6)</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of APG101</measure>
    <time_frame>ongoing during study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>until progression of underlying disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rates (OR)</measure>
    <time_frame>ongoing during study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DR) in responders</measure>
    <time_frame>ongoing during study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>until study and after end of study (by 8-weekly phone calls)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>ongoing during study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function</measure>
    <time_frame>ongoing during study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>Re-Irradiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>33% of the patients will be randomized to reirradiation (RT) alone. They will receive 36 Gy (2 Gy per fraction)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Re-Irradiation + APG101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>66% of the patients will be randomized to reirradiation (RT) + 400 mg APG101 weekly. They will receive 36 Gy (2 Gy per fraction) and 400 mg APG101 weekly as an intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APG101</intervention_name>
    <description>400mg weekly as intravenous infusion</description>
    <arm_group_label>Re-Irradiation + APG101</arm_group_label>
    <other_name>Recombinant fusion protein</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood drawing</intervention_name>
    <description>Blood drawings, e.g. for safety labs, abdominal ultrasound, ECG. Re-Irradiation is not considered a study procedure, but standard of care (inclusion criterion)</description>
    <arm_group_label>Re-Irradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients with a recurrence / progression of glioblastoma either not&#xD;
             being eligible for tumour resection or having macroscopic residual tumour after&#xD;
             resection of the recurrence&#xD;
&#xD;
          -  Diagnosis of glioblastoma must be proven histologically and progress must be&#xD;
             documented by MRI. MRI images must not be older than 2 weeks before first dosing/start&#xD;
             of RT&#xD;
&#xD;
          -  Not more than two prior therapy regimens including one or two resections, one or two&#xD;
             chemotherapies of which one must have been TMZ-containing and one radiotherapy (RT)&#xD;
             for the brain tumour&#xD;
&#xD;
          -  Previous irradiation therapy of the primary tumour with a maximal dose of 60 Gy; at&#xD;
             least 8 months since the end of preirradiation&#xD;
&#xD;
          -  Candidate for reirradiation with recurrent tumour visible on MRI-T1 (Gd) and with the&#xD;
             largest diameter measuring 1 cm to 4 cm&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Age at least 18 years, smoking or non-smoking, of any ethnic origin&#xD;
&#xD;
          -  Karnofsky performance index (KPI) ≥ 60%&#xD;
&#xD;
          -  Neutrophile counts &gt; 1500/μl / Platelet counts &gt; 80.000/μl / Haemoglobin &gt; 10 g/dl /&#xD;
             Serum creatinine &lt; 1.5-fold upper normal range / Bilirubin, AST or ALT &lt; 2,5-fold&#xD;
             upper normal range unless attributed to anticonvulsants / Alkaline phosphatase &lt;&#xD;
             2,5-fold upper normal range&#xD;
&#xD;
          -  Adequate contraception&#xD;
&#xD;
          -  Stable or decreasing treatment with steroids within 5 days before treatment start&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than one RT of brain, prior first radiotherapy with more than 60 Gy&#xD;
&#xD;
          -  Cumulative total dose on the optical chiasm &gt;54 Gy for 2 Gy/fraction, α/β=2&#xD;
&#xD;
          -  Prior treatment with bevacizumab, iodine seeds and/or brachytherapy&#xD;
&#xD;
          -  Unable to undergo MRI&#xD;
&#xD;
          -  Past medical history of diseases with poor prognosis according to the judgement of the&#xD;
             Investigator, e.g. severe coronary heart disease, severe diabetes, immune deficiency,&#xD;
             residual deficits after stroke, severe mental retardation&#xD;
&#xD;
          -  HIV or hepatitis infection&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Treatment within any other clinical trial parallel to the treatment phase of the&#xD;
             current study or within 30 days before inclusion&#xD;
&#xD;
          -  Known active coronary artery disease, significant cardiac arrhythmias or severe&#xD;
             congestive heart failure (NYHA class III - IV)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Wick, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Heidelberg, Dept. of Neurooncology, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Universität Graz, Universitätsklinik für Neurologie Landeskrankenhaus Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Neurologie, Landeskrankenhaus Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landesnervenklinik Wagner-Jauregg, Innere Medizin mit Neuroonkologie</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Wien, Klinische Onkologie</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitätsmedizin Berlin, Klinik für Neurochirugie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Universitätsklinik am Knappschaftskrankenhaus</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Universitätsklinik Bonn, Schwerpunkt klinische Neuroonkologie</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Dresden, Klinik und Poliklinik für Neurochirurgie</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt/Oder, Klinik für Strahlentherapie/Radioonkologie</name>
      <address>
        <city>Frankfurt/Oder</city>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Hamburg, Klinik für Neurochirugie</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Heidelberg, Abteilung Neuroonkologie</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Leipzig, Klinik für Strahlentherapie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim, Klinik für Neurochirurgie</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philipps-Universität Marburg, Klinik für Neurologie</name>
      <address>
        <city>Marburg</city>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU München, Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Campus Großhadern &amp; Campus Innenstadt</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Strahlentherapie/Radiologische Onkologie, Klinikum rechts der Isar, TU München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städt. Kliniken München GmbH, Klinikum Bogenhausen, Abt. Neurochirurgie</name>
      <address>
        <city>München</city>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik der Universität Regensburg, Im Bezirksklinikum</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart, Neurozentrum Neurochirurgie</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tuebingen, Strahlenonkologie</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Ulm, Klinik für Strahlentherapie und Radioonkologie</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>February 18, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <last_update_submitted>June 15, 2015</last_update_submitted>
  <last_update_submitted_qc>June 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma Multiforme</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

